ZIOPHARM ONCOLOGY INC Human Resources Contracts & Agreements
49 Contracts & Agreements
- Bonus & Incentive Agreements (10 contracts)
- Consulting Agreements (6)
- Employment Agreements (24)
- Retention Agreements (2)
- Separation Agreements (5)
- Severance Agreements (2)
- Consulting Agreement, dated as of February 21, 2024, between the Registrant and Ferdinand Groenewald (Filed With SEC on April 1, 2024)
- Consulting Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr (Filed With SEC on April 1, 2024)
- Separation Agreement, dated as of December 22, 2023, between the Registrant and Kevin S. Boyle, Sr (Filed With SEC on April 1, 2024)
- Consulting Agreement, dated as of November 14, 2023, between the Registrant and Melinda Lackey (Filed With SEC on April 1, 2024)
- Retention Agreement, dated as of August 14, 2023, between the Registrant and Drew Deniger (Filed With SEC on November 14, 2023)
- Retention Agreement, dated as of August 14, 2023, between the Registrant and Melinda Lackey (Filed With SEC on November 14, 2023)
- Separation Agreement, dated March 28, 2022, by and between the Registrant and Dr. Raffaele Baffa (Filed With SEC on March 30, 2022)
- Amendment to Employment Agreement, dated November 23, 2020, by and between the Registrant and Raffaele Baffa (Filed With SEC on March 30, 2022)
- Employment Agreement, dated September 30, 2020, by and between the Registrant and Raffaele Baffa (Filed With SEC on March 30, 2022)
- Amendment to Employment Agreement, dated November 23, 2020, by and between the Registrant and Eleanor de Groot (Filed With SEC on March 30, 2022)
- Employment Agreement, dated April 23, 2019, by and between the Registrant and Eleanor de Groot (Filed With SEC on March 30, 2022)
- Amendment to Employment Agreement, dated November 23, 2020, by and between the Registrant and Jill Buck (Filed With SEC on March 30, 2022)
- Employment Agreement, dated April 23, 2019, by and between the Registrant and Jill Buck (Filed With SEC on March 30, 2022)
- Employment Agreement by and between ZIOPHARM Oncology, Inc. and Kevin S. Boyle, Sr., dated August 24, 2021 (Filed With SEC on August 30, 2021)
- Consulting Agreement by and between the Company and Dr. Laurence Cooper, entered into on April 5, 2021 (Filed With SEC on April 9, 2021)
- Separation Agreement by and between the Company and Dr. Laurence Cooper, dated April 5, 2021 (Filed With SEC on April 9, 2021)
- Employment Agreement by and between Ziopharm Oncology, Inc. and Heidi Hagen, dated February 25, 2021 (Filed With SEC on March 2, 2021)
- Form of Retention Bonus Agreement (Filed With SEC on March 1, 2021)
- Amendment to the Employment Agreement by and between the Registrant and Sath Shukla, dated as of November 23, 2020 (Filed With SEC on March 1, 2021)
- Amendment to the Employment Agreement by and between the Registrant and Robert Hadfield, dated as of November 23, 2020 (Filed With SEC on March 1, 2021)
- Form of Stock Option Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 1, 2021)
- Form of Restricted Stock Agreement Granted Under the ZIOPHARM Oncology, Inc. 2020 Equity Incentive Plan (Filed With SEC on March 1, 2021)
- Consulting Agreement by and between Ziopharm Oncology Inc. and Danforth Advisors LLC, effective as of January 21, 2021 (Filed With SEC on February 23, 2021)
- Ziopharm Oncology, Inc. 2020 Equity Incentive Plan (Filed With SEC on July 1, 2020)
- Separation Agreement and Release by and between the Company and Dr. David Mauney, effective May 26, 2020 (Filed With SEC on May 29, 2020)
- Consulting Agreement by and between the Company and Dr. David Mauney, dated May 26, 2020 (Filed With SEC on May 29, 2020)
- Employment Agreement by and between Ziopharm Oncology, Inc. and Sath Shukla (Filed With SEC on July 24, 2019)
- Employment Agreement, dated as of April 23, 2019, by and between the Company and Robert Hadfield (Filed With SEC on April 29, 2019)
- Employment Agreement, dated as of April 23, 2019, by and between the Company and David Mauney, M.D (Filed With SEC on April 29, 2019)
- Ziopharm Oncology, Inc. 2012 Equity Incentive Plan, as amended (Filed With SEC on September 24, 2018)
- Separation Agreement by and between ZIOPHARM Oncology, Inc. and Caesar J. Belbel dated as of February 15, 2018 (Filed With SEC on February 22, 2018)
- Severance Agreement by and between ZIOPHARM Oncology, Inc. and David M. Mauney, M.D (Filed With SEC on September 28, 2017)
- AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on June 2, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on May 7, 2015)
- ZIOPHARM ONCOLOGY, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MARCH 7, 2012 APPROVED BY THE STOCKHOLDERS: JUNE 20, 2012 AMENDED BY THE BOARD OF DIRECTORS:... (Filed With SEC on August 7, 2014)
- ZIOPHARM ONCOLOGY, INC. 2012 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MARCH 7, 2012 APPROVED BY THE STOCKHOLDERS:JUNE 20, 2012 AMENDED BY THE BOARD OFDIRECTORS:... (Filed With SEC on June 19, 2014)
- AMENDED AND RESTATED SEVERANCE AGREEMENT (Filed With SEC on May 8, 2014)
- AMENDMENT AND EXTENSION TO EMPLOYMENT AGREEMENT (Filed With SEC on January 8, 2014)
- EXTENSION OF EMPLOYMENT AGREEMENT (Filed With SEC on January 8, 2013)
- ZIOPHARMOncology, Inc. 2012 Equity Incentive Plan Form of Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) (Filed With SEC on June 26, 2012)
